Results 101 to 110 of about 4,378 (208)

Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study

Current Problems in Cancer: Case Reports
Triple-negative breast cancer (TNBC) is an aggressive heterogeneous form of breast cancer that accounts for 15 %-20 % of all breast cancers. Characterized by an absence of estrogen receptor, progesterone receptor, and human epidermal growth factor ...
Martin Dietrich, Michel Velez
doaj   +1 more source

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma [PDF]

, 2018
David S. Ziegler, Marie Wong, Chelsea Mayoh, Amit Kumar, Maria Tsoli, Emily Mould, Vanessa Tyrrell, Dong‐Anh Khuong‐Quang, Mark Pinese, Velimir Gayevskiy, Richard J. Cohn, Loretta M. S. Lau, Mark Reynolds, Michael C. Cox, Andrew J. Gifford, Michael Rodriguez, Mark J. Cowley, Paul G. Ekert, Glenn M. Marshall, Michelle Haber   +19 more
openalex   +1 more source

HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours [PDF]

, 2022
Karsten Nysom, François Doz, Birgit Geoerger, Ingrid Øra, Sébastien Perreault, Ricarda Norenberg, Marc Fellous, Esther De La Cuesta, Theodore W. Laetsch, Cornelis M. van Tilburg   +9 more
openalex   +1 more source

CO212 The Potential Long-Term Comparative Effectiveness of Larotrectinib Vs. Immune Checkpoint Inhibitors for Treatment of Metastatic NTRKGene Fusion-Positive Cancers [PDF]

, 2023
Kangho Suh, Kang An, Gyung Hyuck Ko, Todd Williamson, Ning Liao, Sean D. Sullivan   +5 more
openalex   +1 more source

Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies [PDF]

, 2020
Megan Pollack, Karen Keating, Erika Wissinger, Louis Jackson, Evelyn Sarnes, Brian J. Cuffel   +5 more
openalex   +1 more source

A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER” [PDF]

, 2020
Sarika Ogale, Clarissa Emy Higuchi Zerbini, Miranta Antoniou, R. Freund   +3 more
openalex   +1 more source

EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS [PDF]

, 2020
Hiroaki Goto, Birgit Geoerger, Steven G. DuBois, Juneko E. Grilley‐Olson, Cornelis M. van Tilburg, Johannes H. Schulte, Hyoung Jin Kang, Makoto Tahara, Valentina Boni, Sébastien Perreault, Michael Capra, John A. Reeves, Nicoletta Brega, Barrett H. Childs, Theodore W. Laetsch, David S. Ziegler, François Doz   +16 more
openalex   +1 more source

Activity of larotrectinib in patients with TRK fusion GI malignancies [PDF]

, 2018
Michael J. Nathenson, George D. Demetri, Ulrik Lassen, David S. Hong, Valentina Boni, John F. Deeken, Afshin Dowlati, M.C. Cox, N. Ku, Scott Cruickshank, Hope Qamoos, A. Drilon   +11 more
openalex   +1 more source

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers [PDF]

, 2022
Alexander Drilon, Daniel S. W. Tan, Ulrik N. Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Lin Shen, Victor Moreno, Shivaani Kummar, Jessica J. Lin   +14 more
openalex   +1 more source

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer.

European Journal of Cancer
C. Qi, L. Shen, T. André, Hyun Cheol Chung, T.L. Cannon, E. Garralda, A. Italiano, D. Rieke, Tianshu Liu, D. Burcoveanu, Natascha Neu, C. Mussi, Rui-hua Xu, David S Hong, A. Drilon, J. Berlin   +15 more
semanticscholar   +1 more source